Bioject to Report Third Quarter 2010 Financial Results

PORTLAND, Ore.--()--Bioject Medical Technologies Inc., (OTCBB: BJCT), a leading developer of needle-free injection therapy systems, announced today that the Company will report its financial results for the third quarter ended September 30, 2010 on Wednesday, November 10, 2010, after the close of the financial markets. Management will conduct a conference call on Thursday, November 11, 2010 at 10:00 a.m. Eastern Standard Time to review the results for the quarter. Ralph Makar, President and CEO; Dr. Rick Stout, Executive Vice President and Chief Medical Officer; and Chris Farrell, Vice President of Finance, will be hosting the call.

Live audio of the conference call will be available to investors, members of the news media and the general public. To participate in the call via telephone, please dial 1-877-407-8037. A conference call replay will also be available until November 14, 2010, and thereafter, on the Bioject website. To listen to the replay, please dial 1-877-660-6853, replay account number 7303, identification number 360388.

Bioject Medical Technologies Inc., based in Portland, Oregon, is an innovative developer and manufacturer of needle-free injection therapy systems (NFITS). NFITS provide an empowering technology and work by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and depositing medication in the tissue beneath. The Company is focused on developing mutually beneficial agreements with leading pharmaceutical, biotechnology, and veterinary companies.

For more information about Bioject, visit www.bioject.com.

Contacts

Bioject Medical Technologies Inc.
President and CEO
Ralph Makar, 503-692-8001 ext. 4137
or
Vice President of Finance
Chris Farrell, 503-692-8001 ext. 4132

Contacts

Bioject Medical Technologies Inc.
President and CEO
Ralph Makar, 503-692-8001 ext. 4137
or
Vice President of Finance
Chris Farrell, 503-692-8001 ext. 4132